Lyell Immunopharma, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Lyell Immunopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q3 2024.
  • Lyell Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$44.6M, a 12.3% increase year-over-year.
  • Lyell Immunopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$204M, a 7.31% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$235M, a 28.1% decline from 2022.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$183M, a 26.8% increase from 2021.
  • Lyell Immunopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$250M, a 22.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$204M -$44.6M +$6.27M +12.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$210M -$45.8M +$18.1M +28.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$228M -$60.7M +$6.29M +9.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$235M -$52.9M -$44.5M -530% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$190M -$50.9M +$19.4M +27.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$210M -$63.9M -$27.6M -75.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$182M -$67M +$1.19M +1.74% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$183M -$8.4M +$75.3M +90% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$258M -$70.3M -$21.4M -43.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$237M -$36.3M +$26.3M +42% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$263M -$68.1M -$13.1M -23.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$250M -$83.7M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$48.9M -$13.2M -36.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$62.6M +$38.1M +37.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$55M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 -$35.7M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$101M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.